Journal
ONCOLOGIST
Volume 11, Issue 10, Pages 1047-1057Publisher
WILEY
DOI: 10.1634/theoncologist.11-10-1047
Keywords
lapatinib; GW572016; dual tyrosine kinase inhibitor; breast cancer; EGFR; ErbB-1; ErbB-2; HER-2
Categories
Ask authors/readers for more resources
Lapatinib is an oral receptor tyrosine kinase inhibitor, targeting both the ErbB-1 and ErbB-2 receptors. Preclinical in vitro and in vivo models indicate that lapatinib is active as monotherapy, synergistically in combination with trastuzumab, and in trastuzumab-resistant cell lines. Early clinical trials also provide evidence in patients that lapatinib is active against breast cancer. This paper reviews results of phase II and III clinical trials of lapatinib in metastatic breast cancer, evidence for its potential in patients with brain metastases, and current clinical trials as adjuvant treatment in early-stage disease. Our improved understanding of the biology of breast cancer and the use of biomarkers for identification of specific subtypes is allowing us to bring patient-specific novel therapies such as lapatinib to the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available